Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
72 hedge funds and large institutions have $150M invested in Taro Pharmaceutical Industries Ltd. in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
4% more funds holding
Funds holding: 69 → 72 (+3)
24% less capital invested
Capital invested by funds: $197M → $150M (-$46.5M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.25M |
| 2 |
Morgan Stanley
New York
|
+$1.69M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$1.4M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$1.09M |
| 5 |
Millennium Management
New York
|
+$906K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$8.45M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.5M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$802K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$366K |
TARO Hedge Fund Activity: Q2 2022 in Review
72 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2022, worth a combined $150M — down 24% from $197M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TARO positions and 6 closed out — a net gain of 5 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $6.25M. The largest seller was Fidelity Investments, cutting an estimated $10.4M.
- 72 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2022, up from 69 in Q1 2022.
- Funds reported $150M of Taro Pharmaceutical Industries Ltd. stock for Q2 2022, down 24% quarter-over-quarter.
- 11 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2022 and 6 closed out, a net change of +5 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2022 was Armistice Capital, an estimated $6.25M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2022 was Fidelity Investments, an estimated $10.4M sold.
Based on aggregated 13F filings for Q2 2022.